Dna X (SONM) Net Income towards Common Stockholders (2018 - 2025)
Historic Net Income towards Common Stockholders for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to -$4.8 million.
- Dna X's Net Income towards Common Stockholders fell 8921.18% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.0 million, marking a year-over-year decrease of 16253.66%. This contributed to the annual value of -$34.3 million for FY2024, which is 1033701.49% down from last year.
- As of Q3 2025, Dna X's Net Income towards Common Stockholders stood at -$4.8 million, which was down 8921.18% from -$7.5 million recorded in Q2 2025.
- In the past 5 years, Dna X's Net Income towards Common Stockholders ranged from a high of $527000.0 in Q3 2023 and a low of -$22.3 million during Q4 2024
- Over the past 5 years, Dna X's median Net Income towards Common Stockholders value was -$4.2 million (recorded in 2022), while the average stood at -$5.2 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 13277.36% in 2023, then crashed by 229870.69% in 2024.
- Quarter analysis of 5 years shows Dna X's Net Income towards Common Stockholders stood at -$11.7 million in 2021, then soared by 89.91% to -$1.2 million in 2022, then grew by 21.69% to -$928000.0 in 2023, then tumbled by 2298.71% to -$22.3 million in 2024, then soared by 78.65% to -$4.8 million in 2025.
- Its last three reported values are -$4.8 million in Q3 2025, -$7.5 million for Q2 2025, and $458000.0 during Q1 2025.